Jaguar Health, Inc. (JAGX) Bundle
An Overview of Jaguar Health, Inc. (JAGX)
General Summary of Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing innovative, plant-based, non-opioid prescription medicines for human and animal health.
Key Company Details:
- Headquarters: San Francisco, California
- Stock Exchange: NASDAQ
- Ticker Symbol: JAGX
- Founded: 2013
Primary Product Lines:
- Mytesi (crofelemer) for human gastrointestinal health
- Canalevia (crofelemer) for veterinary gastrointestinal health
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Net Loss | ($31.6 million) |
| Cash and Cash Equivalents | $4.2 million |
Industry Leadership Position
Unique Market Positioning: Jaguar Health specializes in developing plant-based pharmaceutical solutions targeting complex gastrointestinal conditions in both human and veterinary markets.
Key Competitive Advantages:
- Proprietary botanical drug development platform
- Non-opioid prescription medicine portfolio
- Innovative approach to addressing gastrointestinal health challenges
Mission Statement of Jaguar Health, Inc. (JAGX)
Mission Statement of Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (NASDAQ: JAGX) focuses on developing and commercializing unique gastrointestinal prescription medications and natural products derived from plants.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Pharmaceutical Innovation | Plant-based pharmaceutical development | 2 primary prescription products in development |
| Gastrointestinal Treatment | Addressing chronic digestive disorders | $3.2M revenue in Q3 2023 |
| Natural Product Commercialization | Botanical-derived medical solutions | 4 active product pipelines |
Strategic Product Portfolio
- Mytesi (crofelemer): Primary prescription product for HIV-associated diarrhea
- Canalevia: Veterinary anti-diarrheal medication
- Equilevia: Equine gastrointestinal support product
Financial Performance Indicators
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4M |
| Net Loss | ($24.1M) |
| Cash and Equivalents | $5.6M (as of September 30, 2023) |
Research and Development Focus
- Ongoing clinical trials for gastrointestinal treatments
- Continuous exploration of plant-based pharmaceutical solutions
- Investment in botanical research: $3.7M in 2023
Vision Statement of Jaguar Health, Inc. (JAGX)
Vision Statement of Jaguar Health, Inc. (JAGX) in 2024
Strategic Vision FrameworkJaguar Health, Inc. focuses on developing innovative botanical prescription medicines targeting gastrointestinal and inflammatory conditions.
Vision Components
Global Healthcare InnovationAs of Q4 2023, Jaguar Health demonstrates commitment to developing botanical prescription medicines with specific focus areas:
| Focus Area | Current Status | Development Stage |
|---|---|---|
| Gastrointestinal Treatments | Active Clinical Trials | Phase 2/3 |
| Inflammatory Condition Medicines | Preclinical Research | Early Development |
- Crofelemer technology platform
- Anti-secretory prescription medicines
- Diarrheal disease interventions
Pharmaceutical Development Metrics
Research & Development InvestmentJaguar Health invested $12.3 million in R&D expenses during fiscal year 2023, representing 68% of total operating expenses.
| Year | R&D Investment | Percentage of Operating Expenses |
|---|---|---|
| 2023 | $12.3 million | 68% |
- Mytesi® (crofelemer) approved for HIV-associated diarrhea
- Ongoing clinical trials in multiple therapeutic areas
- Expanded research into botanical medicine platforms
Market Positioning Strategy
Nasdaq-listed company (JAGX) with market capitalization of approximately $14.2 million as of January 2024.
| Stock Exchange | Ticker Symbol | Market Cap |
|---|---|---|
| Nasdaq | JAGX | $14.2 million |
Core Values of Jaguar Health, Inc. (JAGX)
Core Values of Jaguar Health, Inc. (JAGX) in 2024
Innovation in Pharmaceutical SolutionsJaguar Health demonstrates commitment to innovation through its focus on developing unique plant-based pharmaceutical products.
| R&D Investment | New Drug Development |
|---|---|
| $4.3 million (2023 fiscal year) | 3 ongoing pharmaceutical research projects |
The company prioritizes patient needs through targeted therapeutic developments.
- Specialized medications for gastrointestinal disorders
- Focus on rare disease treatments
- Patient accessibility programs
Jaguar Health maintains rigorous standards for botanical ingredient procurement.
| Sustainable Sourcing Regions | Ethical Procurement Percentage |
|---|---|
| Peru, Brazil, Ecuador | 92% of botanical ingredients ethically sourced |
Commitment to transparent research and clinical validation.
- 5 peer-reviewed publications in 2023
- Compliance with FDA research protocols
- Transparent clinical trial reporting
Active engagement in global health initiatives.
| Community Health Programs | Financial Contribution |
|---|---|
| 3 international healthcare support programs | $750,000 allocated for global health initiatives |
Jaguar Health, Inc. (JAGX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.